Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: This study aimed to evaluate the effect of metformin and sulfonylurea (SUs) medication time on Diabetic retinopathy (DR) among newly diagnosed patients with type 2 diabetes (T2DM) using a pooled analysis. This study aimed to evaluate the effect of metformin and SUs' medication time on DR among newly diagnosed T2DM using a pooled analysis.
Methods: The data of 4,068 newly diagnosed DM individuals(mean age, 60.2 ± 0.85 years) from three prospective cohorts of Tehran Sugar and Lipid Study (TLGS), Multi-Ethnic Study of Atherosclerosis (MESA), and Atherosclerosis Risk in Communities (ARIC) with a mean age of 59.6 ± 08 years were pooled. The cumulative exposure to metformin, SUs, aspirin, statin, and anti-hypertensive medication was also determined using the same approach. The Cox proportional hazards (CPH) model was used to calculate the hazard ratio (HR) (95% CI) for the outcomes while adjusting for confounding factors such as fasting Blood Sugar (FBS), age, statin, aspirin, and anti-hypertensive medications.
Results: During follow-up, DR occurred in 519 DM. Metformin alone, SUs alone, and the combination of both reduced the hazard of DR by 10%, 7%, and 11% for each year of use, respectively (p < 0.05). The protective effect of metformin and SUs, individually or in combination, on DR started approximately five years after the initial treatment and continued until approximately 15 years after the initial treatment and then reached a plato.
Conclusion: Long-term treatment with metformin and SUs, individually and in combination, was associated with a reduced risk of DR in people with newly diagnosed diabetes for up to a decade compared with no treatment. These findings highlight the protective role of metformin and sulfonylureas as inexpensive and readily available drugs to prevent DR in people with newly diagnosed diabetes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784098 | PMC |
| http://dx.doi.org/10.1186/s40942-025-00637-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Epidemiology, Real-World Treatment, and Economic Burden of Waldenström Macroglobulinemia: A Comprehensive Analysis Based on Anonymized Claims Data Between 2010 and 2022.
Value Health Reg Issues
September 2025
Department of Hematology and Medical Oncology, University Medical School Mainz, Mainz, Germany.
Objectives: This study aimed to provide evidence on the epidemiology, real-world treatment patterns, overall survival, and economic burden of Waldenström macroglobulinemia (WM).
Methods: A retrospective analysis of an anonymized large German claims database from January 1, 2010, to June 30, 2022, identified incident WM cases based on a 12-month diagnosis-free period before the first confirmed WM diagnosis (ICD-10-GM code C88.0).
Risk Factors for Hyperglycemic Emergency Department Visits in Newly Diagnosed Type 2 Diabetes: History of Depression as a Key Predictor.
J Prim Care Community Health
September 2025
Department of Family Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI, USA.
Aims: To identify risk factors for hyperglycemia in emergency department visits within 1 year following type 2 diabetes diagnosis.
Methods: In this retrospective cohort study, electronic medical record data from 3333 adult patients newly diagnosed with type 2 diabetes across 57 primary care clinics in West Michigan between April 2021 and January 2023 were analyzed. The primary outcome was hyperglycemia at ED encounters within 12 months of diagnosis.
Polypill in heart failure: a pathway to simplified treatment and improved adherence and outcomes.
Heart Fail Rev
September 2025
Department of Medicine, Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
Heart failure (HF) remains a global health challenge that imposes significant clinical and economic burden. Treatment adherence to guideline-directed medical therapy (GDMT) remains a major challenge in the management of HF, despite the availability of guideline-directed medical therapy (GDMT). Polypharmacy and regimen complexity contribute to poor adherence, particularly among older adults and in resource-limited settings.
View Article and Find Full Text PDFMolecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a NM umbrella trial.
Nat Med
September 2025
Neurology, University Clinic Heidelberg, Heidelberg University & German Cancer Consortium (DKTK) and CCU Neurooncology, German Cancer Research Center, Heidelberg, Germany.
Advances in molecular understanding and diagnostic precision of glioblastoma enable the identification of key genetic alterations in a timely manner and, in principle, allow treatments with targeted compounds based on molecular markers. Here we report the results of the phase 1/2 umbrella trial NCT Neuro Master Match (NM), which evaluated targeted treatments in 228 patients with newly diagnosed glioblastoma without O6-methylguanine DNA-methyltransferase promoter hypermethylation. Stratification for treatment was conducted by a trial-specific molecular tumor board across five subtrials, each evaluating a targeted therapy-alectinib, idasanutlin, palbociclib, vismodegib or temsirolimus-selected according to the best-matching molecular alteration.
View Article and Find Full Text PDFCorrection: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial.
Leukemia
September 2025
National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.